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• Approximately 80% of lung cancer cases are non-small cell lung cancer (NSCLC). 2 • Most patients present with disease that is inoperable, stage IV or metastatic. 3 • Treatment of advanced NSCLC involves balancing the effi cacy and tolerability of treatments. This balance includes consideration of the effects of treatment on disease progression.
• The current report describes fi ndings from a prospective medical record registry of patients newly diagnosed with advanced NSCLC who received any of three common regimens as fi rst line treatment. The focus of this report is progression free survival (PFS), overall survival (OS), toxicity, and health-related quality of life (HRQOL) through one year of follow-up.
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• To assess differences in effectiveness outcomes (PFS and OS) by treatment regimens in patients receiving fi rst line treatment of advanced NSCLC in real world community oncology settings.
• To examine demographic and clinical characteristics by fi rst line treatment regimen.
• To examine the occurrence of a set of selected adverse events, by fi rst line treatment regimen.
• To assess the impact of treatment regimen on HRQOL among patients receiving fi rst line treatment of advanced NSCLC.
OBJECTIVES
The study was a prospective observational study that examined effectiveness outcomes, toxicities, and HRQOL measured by patient reported outcomes (PROs) in patients newly diagnosed with advanced NSCLC, treated with one of three commonly used regimens, through one year of follow-up. Key design elements included:
• Study Design ○ Hybrid study design that combined prospective and retrospective elements.
○ Eligible patients prospectively identifi ed and consented. ○ Symptom burden and HRQOL measures prospectively collected over 12 months from start of fi rst line therapy.
○ Clinical data were collected at two time points: 1) Patient enrollment during cycle 1 or 2 of fi rst line therapy, 2) End of study at 12 months or death, whichever occurred fi rst.
○ All clinical data were collected from the existing electronic medical records, which were created as part of routine clinical care at participating practices.
○ Baseline clinical data were collected at time point #1, and included planned treatment, performance status, comorbid disease burden, and sites of metastatic disease.
○ Follow-up clinical data were collected at time point #2, and included dates of treatment, changes in treatment, toxicities, and effectiveness outcomes including PFS and OS. Disease progression was identifi ed based on scan records and physician progress notes. ○ Cox regression analysis to examine PFS and OS, controlling for demographic and clinical covariates.
○ Descriptive methods to examine adverse events. Chi-square and Exact tests were used to compare event rates across treatment groups.
○ Linear Mixed models to assess change in PROs over time, from start of fi rst line treatment of advanced NSCLC, through disease progression, for up to 12 months of follow-up after start of fi rst line therapy. Models also examined treatment group differences, controlling for demographic and clinical covariates (age, gender, race, stage at diagnosis, performance status, body mass index, insurance, smoking status, comorbidities).
○ Kaplan-Meier analysis, with log rank test, to examine time to deterioration for PRO endpoints.
○ Analyses were conducted with classifi cation based on actual treatment received. Analysis by intent to treat showed very similar patterns, but with slightly smaller effects.
METHODS

Descriptive Statistics
• Of 155 eligible patients, 147 provided baseline and follow-up outcomes data, and 145 provided PRO data.
• Of the 147, 66 (44.9%) received Regimen A, 25 (17.0%) Regimen B, and 56 (38.1%) Regimen C. • Patients were 58.5% male, 86.4% white race, with mean age 64.8 years. 13.6% had impaired performance status. More than 90% of patients had a smoking history (see Table 1 and Table 2 ).
• Race and geographic region varied across Regimen groups (p = 0.0054, p = 0.0277, respectively), with fewer white patients in Regimen B; and fewer patients from the South in Arm C. Stage at initial diagnosis, performance status, and rates of baseline brain, bone, and liver metastasis did not differ across groups. However, the rate at which patients received radiation therapy in the advanced setting was higher in Regimen C than in A and B (41.1%, vs. 12.1% and 16.0%, respectively, p = 0.0006; see Table 1 ).
Effi cacy Outcomes
• Median PFS in fi rst line was 5.59 months overall, with 141 events in 147 patients.
• Unadjusted PFS varied signifi cantly by treatment group (Regimen A: 7.36 months, Regimen B: 4.18, Regimen C: 4.96), p = 0.0013 (see Figure 1 ).
• Cox regression analysis of PFS, controlling for demographic and clinical covariates, shows signifi cant variability in PFS by treatment regimen, p = 0.0115 (see Table 3 ). Pairwise comparisons shows Regimen A was associated with longer PFS than Regimen B (p = 0.0035), and tended to be associated with longer PFS than Regimen C (p = 0.1070). Impaired performance status was associated with shorter PFS (HR = 2.463, p = 0.0011). Other covariates were nonsignifi cant.
• Median OS from start of fi rst line was 9.67 months overall, with 102 events observed.
• Unadjusted OS varied signifi cantly by treatment group (Regimen A: 12.30 months, Regimen B: 5.88, Regimen C: 7.92), p < 0.0001 (see Figure 2 ).
• Cox regression analysis of OS, controlling for demographic and clinical covariates, shows signifi cant variability in OS by treatment regimen, p = 0.0040 (see Table 4 ). Pairwise comparisons shows Regimen A was associated with longer OS than Regimen B (p = 0.0012) and Regimen C (p = 0.0354). Male gender, stage IV at diagnosis, impaired performance status, and higher comorbid disease burden were associated with shorter OS.
Patient-Reported Outcomes and Tolerability
• Ninety-three patients (63.3%) had at least one adverse event during treatment of advanced NSCLC, with no signifi cant differences among regimens in the rate at which patients had an adverse event (Regimen A: 71.2%, Regimen B: 56.0%, Regimen C: 57.1%), p = 0.1955. No group differences were present at the level of system organ class, except for musculoskeletal events (Regimen A: 0%, Regimen B: 8%, Regimen C: 5.4%, p = 0.042).
• PRO analysis was based on 145 patients, with 1,100 individual PRO surveys. 59 patients provided PRO data after disease progression.
○ Results from the linear mixed models generally showed no differences in PROs over time across treatment regimen groups. See Figure 3 for QLQ-C30 Global Health Scale results.
○ Results from Kaplan-Meier analysis of time to deterioration (TTD) also generally showed no differences in TTD across treatment regimen groups. See Figure 4 for results for QLQ-C30 Global Health Scale results, where deterioration
RESULTS
LIMITATIONS
• Small sample size (N = 147).
• Observational study design, which necessarily involves nonequivalent comparison groups that may have differed at baseline on unmeasured variables. • Most patients were treated in community oncology settings.
Findings may not generalize to patients treated in other settings.
CONCLUSIONS
• Bevacizumab containing regimens were associated with longer PFS and longer OS compared with non-bevacizumab containing regimens.
• Rate of adverse events was nominally higher in bevacizumabcontaining regimens, but rate differences among treatment groups were nonsignifi cant.
• PROs during fi rst line treatment, and time to deterioration as measured by PROs, did not differ by treatment regimen. 
